GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
| Business Activity | PASS |
| Debt Ratio | — |
| Cash Ratio | — |
| Receivables Ratio | — |
| Revenue Ratio | — |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-07-28 | 1.24 | Pending | — |
| 2026-04-29 | 1.16 | 1.26 | +7.9% |
| 2026-02-04 | 0.62 | 0.70 | +11.9% |
| 2025-10-29 | 1.26 | 1.46 | +15.4% |
| 2025-07-30 | 1.11 | 1.24 | +11.7% |
| 2025-04-30 | 1.04 | 1.20 | +15.6% |
| 2025-02-05 | 0.49 | 0.58 | +18.8% |
| 2024-10-30 | 1.16 | 1.29 | +11.0% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7.6B | $1.7B | $2.8B | $5.8B | $2.3B | 0.86 |
| 2025-12-31 | $8.6B | $636.0M | $1.1B | $6.0B | $1.5B | 0.32 |
| 2025-09-30 | $8.5B | $2.0B | $3.4B | $6.3B | $2.6B | 1.00 |
| 2025-06-30 | $8.0B | $1.4B | $3.2B | $5.8B | $2.0B | 0.71 |
| 2025-03-31 | $7.5B | $1.6B | $3.1B | $5.6B | $2.2B | 0.79 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-15 | Barron (Hal V) | 74 | $3.7K | |
| 2026-04-27 | Conrad (D) | 13 | $709.0 | |
| 2026-04-22 | Martinez-Davis (Maya) | 6 | $334.0 | |
| 2026-04-14 | Martinez-Davis (Maya) | 293 | $17.3K | |
| 2026-04-14 | Martinez-Davis (Maya) | 152 | $8.9K | |
| 2026-04-14 | Ramakrishnan (Shobie) | 601 | $35.6K | |
| 2026-04-13 | Conrad (D) | 11 | $641.0 | |
| 2026-04-13 | Conrad (D) | 65 | $3.8K | |
| 2026-04-09 | Barron (Hal V) | 26 | $1.5K | |
| 2026-04-09 | Beal (Anne M.D.) | 32 | $1.9K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| FMR, LLC | 67.7M | $3.5B | 0.0% |
| Dodge & Cox Inc. | 58.7M | $3.0B | 0.0% |
| Fisher Asset Management, LLC | 34.5M | $1.8B | 0.0% |
| Primecap Management Company | 25.2M | $1.3B | 0.0% |
| Acadian Asset Management. LLC | 11.8M | $606.1M | 0.0% |
| Wellington Management Group, LLP | 11.7M | $602.1M | 0.0% |
| Morgan Stanley | 11.0M | $566.8M | 0.0% |
| Goldman Sachs Group Inc | 9.6M | $492.7M | 0.0% |
| JTC Employer Solutions Trustee Ltd. | 9.0M | $464.6M | 0.0% |
| Royal Bank of Canada | 7.5M | $385.7M | 0.0% |
Buy
Hold
Sell
Strong Sell
$221.8B
4.26
0.298
8
$32.8B
$19.1B
+8.4%
3.5%
2.88
3.05
0.0%
66,841
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-07-28 | $1.24 | Pending | — |
| 2026-04-29 | $1.16 | $1.26 | +7.9% |
| 2026-02-04 | $0.62 | $0.70 | +11.9% |
| 2025-10-29 | $1.26 | $1.46 | +15.4% |
| 2025-07-30 | $1.11 | $1.24 | +11.7% |
| 2025-04-30 | $1.04 | $1.20 | +15.6% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($57.66, 8 analysts) | |||
| 10 | $495.75 | +$80.90 (16%) | 1.1R |
| 50 | $2,478.75 | +$404.50 (16%) | 1.1R |
| 100 | $4,957.50 | +$809.00 (16%) | 1.1R |
| To Fair Value ($62.80) | |||
| 10 | $495.75 | +$132.20 (27%) | 1.8R |
| 50 | $2,478.75 | +$661.00 (27%) | 1.8R |
| 100 | $4,957.50 | +$1,322.00 (27%) | 1.8R |
- Elevated short interest (3.05 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| GSK.L | 0.768 |
| NVS | 0.622 |
| AZN | 0.574 |
| XLV | 0.541 |
| AMGN | 0.511 |
| Ticker | Correlation |
|---|---|
| VIA | -0.182 |
| BNO | -0.180 |
| USO | -0.166 |
| ISUS.L | -0.158 |
| LPTVQ | -0.157 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.
Related Tickers
Similar in Healthcare
Also in TE500